A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet

Alexandra Ducancelle (1) , Gaël Champier , Sophie Alain (2, 3) , Françoise Petit , Marie-José Sanson Le Pors , Marie-Christine Mazeron (1)

1 Hôpital Lariboisière
2 UNILIM - Université de Limoges
3 EA3175 - Biologie moléculaire et cellulaire des microorganismes

Foscarnet is currently licensed for the treatment of human cytomegalovirus (HCMV) infection. Mutations proven to confer resistance to foscarnet have mostly been mapped to regions II, III and VI of the HCMV UL54-encoded DNA polymerase. We previously showed that sequential foscarnet-resistant HCMV isolates recovered from a patient with lymphoma had change N495K in region delta-C of the DNA polymerase. To evaluate the impact of change N495K on HCMV sensitivity to foscarnet, a recombinant HCMV strain carrying the mutation was produced by homologous recombination. The recombinant virus showed a 3.4-fold increase in foscarnet resistance, and remained sensitive to ganciclovir and cidofovir. In addition, the recombinant strain showed a reduction of infectious virus yield compared with its parent strain. Change N495K should be added to the list of mutations conferring resistance to foscarnet and be taken into account in the genotypic diagnosis of antiviral resistance.

Domaines: Bactériologie; Virologie; Maladies infectieuses

Alexandra Ducancelle, Gaël Champier, Sophie Alain, Françoise Petit, Marie-José Sanson Le Pors, et al.. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. Antiviral Therapy, 2006, 11 (4), pp.537-540. ⟨hal-00405899⟩